792 3.54% Total Liabilities 14,917 14,605 312 2.14% Total Equities 8,221 7,741 480 6.20% http://www.aapico.com/ http://www.aapico.com/ 99 หมู่ท่ี 1 นิคมอุตสาหกรรมไฮเทค ต าบลบา้นเลน อ าเภอบางปะอิน
Change 2021 2020 Amount % Change Total Assets 23,201 22,346 855.33 3.83% Total Liabilities 14,390 14,605 -214.46 -1.47% Total Equities 8,811 7,741 1,069.78 13.82% For the 3rd quarter of 2021, the Company’s
Amount % Change Total Assets 23,772 22,722 1,049 4.6% Total Liabilities 14,469 13,908 561 4.0% Total Equities 9,303 8,815 488 5.5% For the first quarter of 2022, the Company’s total assets increased by
) Financial Position Analysis March December Change 2023 2022 Amount % Change Total Assets 25,753.5 25,469.0 284.5 1.1% Total Liabilities 15,233.0 15,539.5 -306.6 -2.0% Total Equities 10,520.5 9,929.5 591.0 6.0
Administration (CFDA) at the beginning of 2 0 1 8 as the Company had to redesign its packaging to comply with the requirements of the license. Furthermore, the Company also found it necessary to adjust its sales
year to be in parallel with the plunge in sales revenue. Nevertheless, some of the sales expenses did not adjust promptly and did not fully mirror the slowdown in revenue as there is a lead time for
ongoing outbreak of COVID–19, forcing many customers to adjust their working method which have an effect on the operation and delivery of the Company's projects that cause the operation to be delayed than
reducing production cost and also negotiating with customers to review and adjust selling price every quarter. 2.2. Distribution costs for 2018 was in the amount of 4.95 million baht, increased by 1.16
with the plunge in sales revenue. Nevertheless, some of the sales expenses did not adjust promptly and did not fully mirror the slowdown in revenue as there is a lead time for certain expenses that the
granted a license from China Food and Drug Administration (CFDA) during the beginning of 2018 as the Company had to redesign and adjust product packaging according to the granted license as well as change